AveragePenny
10月前
Dyadic International Inc. ( $DYAI ): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
https://thestreetreports.com/dyadic-international-inc-dyai-bird-flu-vaccine-development-amid-rising-pandemic-concerns/
In response to this looming threat, the U.S. government has initiated discussions with Moderna (NASDAQ: MRNA) regarding an avian flu vaccine. Other companies, such as Pfizer (NYSE: PFE), Novavax (NASDAQ: NVAX), BioNTech (NASDAQ: BNTX), and Dyadic International Inc (NASDAQ: DYAI), may also be involved.
Outbreaks naturally cause concern, prompting companies to find solutions. On May 22, Australia reported its first human bird flu case, followed by a second U.S. case involving a Michigan farm worker. This surge in cases has spurred the U.S. government to engage with Moderna for vaccine development. Dyadic International Inc (NASDAQ: DYAI) is a key player to watch, given its proactive approach and promising bird flu vaccine candidate developed in collaboration with ViroVax.
Dyadic’s H5 bird flu vaccine candidate, offers significant advantages in terms of lower costs and accelerated manufacturing. Pre-clinical animal data ViroVax showed high neutralizing antibodies for three distinct H5 viruses, indicating its potential use in both cattle and humans. Scalability and flexibility are strengths of the Dyadic vaccine candidate, positioning it as a dynamic solution for a global health crisis.
The C1 production platform used by Dyadic is sustainable and cost-effective compared to MRNA and other vaccine production processes. This makes Dyadic International a crucial player in addressing the bird flu threat and ensuring preparedness for a potential outbreak.
AveragePenny
1年前
$DYAI Dyadic International, Inc Invites You to Join Us at The Microcap Conference
https://www.newsfilecorp.com/release/194733/Dyadic-International-Inc-Invites-You-to-Join-Us-at-The-Microcap-Conference
Jupiter, Florida--(Newsfile Corp. - January 22, 2024) - Dyadic International, Inc (NASDAQ: DYAI), Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health., will be participating in The Microcap Conference, which will take place January 30, 31, February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.
Ping Rawson, CFO, will be presenting on January 31 & February 1, 2024. Interested parties can register to attend here.
Members of the Dyadic International, Inc management team will also be conducting one-on-one meetings throughout the conference.
To register to attend The Microcap Conference, follow this link.
AveragePenny
1年前
$DYAI "Dyadic International Inc. (NASDAQ: DYAI) Advances Biopharmaceutical Innovations and Vaccine Manufacturing Globally"
https://www.marketscreener.com/quote/stock/DYADIC-INTERNATIONAL-INC-57599342/news/Dyadic-International-Inc-NASDAQ-DYAI-Advances-Biopharmaceutical-Innovations-and-Vaccine-Manufac-45617311/
Dyadic International Inc. (NASDAQ: DYAI), a leading biotechnology firm, focuses on developing innovative microbial platforms to address the increasing global demand for protein bioproduction. Furthermore, the company aims to fulfil unmet clinical and industrial needs by providing cost-effective, accessible, and efficient biopharmaceutical products for both human and animal applications.
Operating from the United States, this company has achieved success in developing a gene expression platform designed for the commercial synthesis of enzymes and various proteins. Utilizing this platform through licensing agreements, the company has leased it to Codexis, Inc. (NASDAQ: CDXS), BASF SE (OTCQX: BASFY, BASF.DE), Abengoa Bioenergy (OTC: AGOAF), and others in the past. In the past two years, the company has constructed another platform named Dapibus(TM), specifically designed to facilitate the production of metabolites, proteins, and other biological products for non-pharmaceutical applications.
Recently, Rubic One Health, the African licensee of Dyadic International, entered into an agreement with Afreximbank to secure funding for a vaccine manufacturing project facility. The vaccines will be produced utilizing Dyadic's C1 protein production platform, and manufacturing operations will take place in South Africa, with distribution planned across the entire continent.
Devoted to assisting its collaborators and partners in creating impactful therapeutic and preventive treatments, the company extends its support to partners in both developed and emerging nations. Dyadic International is actively advancing its microbial platform technologies, which encompass DYAI-100, its candidate for a COVID-19 vaccine. Concurrently, the company is engaged in the progression of additional biologic candidates and vaccines.
On November 20, a significant milestone occurred following the company's disclosure of a partnership agreement signed by Rubic One Health, its African licensee. Dyadic International conveyed that Rubic One Health had entered into an agreement with Afreximbank to secure funding for the project preparation facility dedicated to vaccine manufacturing. The announcement highlighted that the vaccines would be produced utilizing Dyadic's C1 protein production platform, with manufacturing operations set to take place in South Africa and distribution planned across the entire continent.
Additionally, the company broadened its pre-existing licensing arrangement with South African-based Rubic One Health. Under the terms of this extended agreement, Rubic is set to utilize Dyadic International's C1 platform for the exploration, development, and cost-effective, high-quality manufacturing of vaccines, catering to both human and animal use. The expanded licensing agreement emphasizes the distribution of these vaccines primarily in the African market. The recognition of the imperative to produce vaccines in Africa became evident with the signing of this deal by Rubic One Health.
Dyadic International, Inc. (NASDAQ: DYAI) is trading above is 30-day and 60-day averages at $1.58 and is position below its 20, 50, and 200-day moving averages, with a 52-week peak at $2.40, suggesting consolidation and signaling a potential transition to an upward trajectory. Considering these indicators, DYAI is a stock that warrants close monitoring in the current period and in the coming weeks.
AveragePenny
1年前
$DYAI Some of the Best Ideas from the 12th Annual Benchmark Discovery Conference
https://www.nasdaq.com/articles/some-of-the-best-ideas-from-the-12th-annual-benchmark-discovery-conference
Conference season in the investment industry may be starting to wind down, but several reputable and well-known names have just wrapped up their annual conferences. One of the most recent conferences to wrap up was the Discovery Conference, hosted by The Benchmark Company. The annual conference gives companies opportunities for one-on-one meetings with institutional investors from across the U.S. Here are some of the best ideas from this year's Discovery Conference.
Dyadic
Dyadic (DYAI) is an interesting biotechnology company working on a wide range of products for human health, animal health and alternative proteins. First, the company is applying its proprietary and patented C1 technology to develop vaccines and antibodies for infectious diseases in humans.
During the first quarter, Dyadic began dosing in a Phase 1 clinical trial of DYAI-100, a COVID-19 booster vaccine candidate based on recombinant protein. The company expects the results from this first in-human trial to accelerate the adoption of the C1-cell protein production platform.
In addition to the COVID-19 vaccine, Dyadic is also developing several other vaccines for infectious diseases, including influenza, and other illnesses, including cancer. The company is using the same C1 platform to develop vaccines and antibodies for infectious diseases in animals, with a focus on Rift-Valley fever, salmonellosis, zoonotic influenza, West Nile virus, coronavirus, plague, rabies, Lyme disease and brucellosis.
Finally, Dyadic's alternative proteins program is aimed at reducing the cost of recombinant protein production using its proprietary Dapibus platform and other technologies in the search for non-pharmaceutical recombinant proteins. As part of this last program, Dyadic has launched a strategic partnership with a global food ingredient company and is exploring licensing and product opportunities in the alternative meat industry.
Investing in high-growth sectors
All the companies on this list operate in high-growth sectors and are developing cutting-edge technologies in their fields with the potential for tremendous gains in the future. For example, one estimate pegged the quantum-computing market at $812.6 million in revenue for 2022, with a projected compound annual growth rate (CAGR) of 22% between 2023 and 2030, bringing it to $8.2 billion in revenue.
Meanwhile, another estimate suggested the blood glucose monitoring device market was worth $12.5 billion in 2022 and projected a CAGR of 8.13% between 2023 and 2030. In fact, Know Labs could eventually address many more markets than just blood glucose monitoring with its technology, so these numbers probably represent only a fraction of the company’s potential total addressable market (TAM).
Ideal Power already addresses a large number of energy-efficient markets. However, one firm estimated that EVs alone represented a $49.1 billion market in 2022 and projected a CAGR of more than 15.5% between 2023 and 2032, making it worth $215.7 billion. Thus, Ideal Power’s TAM should be significantly larger than this one market alone.
Similarly, Dyadic is working on both vaccines and antibodies for infectious diseases and other illnesses in both humans and animals. However, considering only vaccines for infectious diseases, one estimate pegs the market at $77.6 billion in 2023 with a CAGR of 3.9% between 2023 and 2028, making it worth $93.8 billion.
Of course, despite the large TAMs these companies could see, investors are always advised to do their own due diligence before investing in any company or sector.
blue_skies
2年前
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
https://finance.yahoo.com/news/dyadics-dyai-100-covid-19-133000691.html
In summary, glycoprotein vaccine manufacturing C1 production platform appears
entirely suitable for rapid commercial development of SARS-CoV-2 vaccine, which would
be relatively unaffected by lack of resources, such as shortages of materials (e.g., plastic
bags for insect cell vaccine manufacturing), equipment, expensive media, and cold-chain
freezers. Based on the data of this study and further development under GMP conditions
for the first time, a subunit antigen vaccine produced in C1-cells received regulatory approval to initiate a Phase 1 clinical trial to demonstrate safety and efficacy in humans [55].
The above quote is taken from the published paper.
blue_skies
3年前
i feel its a good buy at this point. Lots of shots on net.
Sorrento Therapeutics - Due to a disagreement between the parties concerning the timing, and terms and conditions, for the entry into a definitive license agreement, both parties mutually agreed not to proceed, effective March 17, 2022
Its a little disconcerting that the understanding between the parties was not clearer at the outset.
Hot Features
プレミアム
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Monksdream
3月前
glenn1919
3月前
